Related Experiment Videos
Structural chemoproteomics and drug discovery
Dongkyu Shin1, Yong-Seok Heo, Kyung Joo Lee
1CrystalGenomics, Inc., Asian Institute for Life Sciences, 388-1 Pungnap-dong, Songpa-gu, Seoul, 138-736, Korea.
Biopolymers
|April 7, 2005
Summary
Structural chemoproteomics accelerates drug discovery using novel technologies for protein structure determination, lead generation, and optimization. This approach yielded potent compounds for obesity, diabetes, cancer, and inflammation.
Area of Science:
- Structural chemoproteomics
- Chemical biology
- Drug discovery
Background:
- Drug discovery is a complex and lengthy process.
- Structural information of target proteins is crucial for rational drug design.
- Existing methods for structure determination and lead optimization can be inefficient.
Purpose of the Study:
- To present novel technologies for accelerating drug discovery based on structural chemoproteomics.
- To demonstrate the application of these technologies in identifying potent drug candidates.
Main Methods:
- Development of Structure-based Protein הספרייה (SPS) technology for efficient protein structure determination.
- Development of Structure-based Compound Profiling (SCP) technology for rapid lead generation.
- Development of Structure-based Drug Fragment (SDF) technology for productive lead optimization.
Main Results:
- Successfully determined multiple 3D structures of target proteins complexed with bioactive molecules.
- Determined the structure of the phosphodiesterase 5 (PDE5)/Viagra complex.
- Identified highly potent compounds effective in animal models for obesity, diabetes, cancer, and inflammation.
Conclusions:
- Structural chemoproteomics offers a powerful platform for accelerating drug discovery.
- The developed SPS, SCP, and SDF technologies significantly enhance the efficiency of lead identification and optimization.
- This integrated approach has the potential to expedite the development of novel therapeutics for various diseases.